WAKIX
pitolisant · Pitolisant GR · Pitolisant HD Small Molecule Target: H3 receptor, H3 receptors
Most recent annual filing: 2026-02-24
Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.
Discovery-stage cell replacement therapy platform developed in collaboration with CiRC Biosciences, targeting refractory epilepsies and treatment-resistant narcolepsy. Two discovery-stage candidates under research collaboration with option to license.
Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.